CNRS UMR8161, National Center for Scientific Research, Institute of Biology of Lille, 59021 Lille, France.
Int J Oncol. 2013 Apr;42(4):1367-75. doi: 10.3892/ijo.2013.1820. Epub 2013 Feb 8.
Egfl7 (VE-statin) is specifically expressed by endothelial cells of normal tissues but its expression is deregulated in human cancers. Analysis of expression of Egfl7 protein and transcripts in 211 human breast cancer samples shows that Egfl7 is strongly expressed by breast tumor cells. Egfl7 expression is significantly higher in invasive ductal than in invasive lobular carcinoma. Expression of Egfl7 transcripts is also higher in lower SBR grade lesions and in lesions which are not associated with lymph node invasion. Within the invasive ductal carcinoma sub-population, expression of Egfl7 transcripts is correlated with the SBR score and with the ER+ status. High transcript and Egfl7 protein levels significantly correlate with the absence of axillary lymph node invasion. In lymph nodes, the levels of Egfl7 are correlated with the histological type of the primary lesions; they are higher in ductal than in lobular carcinoma. Egfl7 expression is thus associated with better prognosis factors and with the absence of lymph node invasion in human breast cancer lesions.
Egfl7（VE-抑制剂）在正常组织的内皮细胞中特异性表达，但在人类癌症中其表达失调。对 211 例人乳腺癌样本中 Egfl7 蛋白和转录本的表达分析表明，Egfl7 在乳腺癌细胞中强烈表达。Egfl7 在浸润性导管癌中的表达显著高于浸润性小叶癌。Egfl7 转录本的表达在较低的 SBR 分级病变和与淋巴结浸润无关的病变中也较高。在浸润性导管癌亚群中，Egfl7 转录本的表达与 SBR 评分和 ER+状态相关。高转录本和 Egfl7 蛋白水平与腋窝淋巴结无浸润显著相关。在淋巴结中，Egfl7 的水平与原发性病变的组织学类型相关；在导管癌中高于小叶癌。因此，Egfl7 的表达与人乳腺癌病变的更好预后因素和无淋巴结浸润相关。
